The somatostatin neuroendocrine system: Physiology and clinical relevance in gastrointestinal and pancreatic disorders

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 18, Issue 4, 2004, Pages 607-622

  Low, Malcolm J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Carcinoid; Diagnostic imaging; Helicobacter; Lanreotide; Neuroendocrine tumor; Octreotide; Somatostatin; Targeted radionuclide therapy

Indexed keywords

ALENDRONIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; ANGIOPEPTIN[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID YTTRIUM 90]; ANTINEOPLASTIC AGENT; BN 81674; CYN 154806; FLUOROURACIL; GHRELIN; MITOMYCIN C; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; PROTON PUMP INHIBITOR; RADIOISOTOPE; SEGLITIDE; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

ABDOMINAL CRAMP; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER ADJUVANT THERAPY; CHOLELITHIASIS; CHRONIC GASTRITIS; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ESOPHAGUS VARICES BLEEDING; FLATULENCE; GASTROINTESTINAL DISEASE; GENE CONTROL; GENETIC TRANSFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; IN VIVO STUDY; INFLAMMATORY CELL; ISOTOPE LABELING; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS DISEASE; PATHOGENESIS; PATHOGENICITY; RADIOISOTOPE THERAPY; REVIEW; SOMATIC GENE THERAPY; SOMATOSTATIN CELL; SOMATOSTATINOMA; STEATORRHEA; STOMACH MUCOSA INJURY; ANIMAL; NEUROSECRETION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; NEUROSECRETORY SYSTEMS; PANCREATIC DISEASES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 8344226077     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2004.08.005     Document Type: Review

References (100)

1. P. Brazeau W. Vale R. Burgus et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone Science 179 1973 77-79
2. R.H. Goodman J.W. Jacobs W.W. Chin et al. Nucleotide sequence of a cloned structural gene coding for a precursor of pancreatic somatostatin Proceedings of the National Academy of Sciences of the USA 77 1980 5869-5873
3. Reichlin S. Somatostatin New England Journal of Medicine 309 1983 1495-1501
4. Reichlin S. Somatostatin (second of two parts) New England Journal of Medicine 309 1983 1556-1563
5. S. Melmed M.L. Vance A.L. Barkan et al. Current status and future opportunities for controlling acromegaly Pituitary 5 2002 185-196
6. A.D. Blake A.C. Badway M.Z. Strowski Delineating somatostatin's neuronal actions Current Drug Targets in Central Nervous System and Neurological Disorders 3 2004 153-160
7. R. Winsky-Sommerer D. Grouselle C. Rougeot et al. The proprotein convertase PC2 is involved in the maturation of prosomatostatin to somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease Neuroscience 122 2003 437-447
8. A.D. Spier L. de Lecea Cortistatin: A member of the somatostatin neuropeptide family with distinct physiological functions Brain Research Reviews 33 2000 228-241
9. Low MJ. Somatostatin. In: H.L. Henry A.W. Norman (Eds.). Encyclopedia of Hormones 2003 Elsevier Science San Diego 379-388
10. J.W. Ensinck E.C. Laschansky R.E. Vogel D.A. D'Alessio Effect of ingested nutrients on the release of thrittene into the human circulation Journal of Clinical Endocrinology and Metabolism 88 2003 4798-4804
11. L.I. Larsson Developmental biology of gastrin and somatostatin cells in the antropyloric mucosa of the stomach Microscopy Research Techniques 48 2000 272-281
12. F.G. Andersen J. Jensen R.S. Heller et al. Pax6 and Pdx1 form a functional complex on the rat somatostatin gene upstream enhancer Federation of European Biochemical Society Letters 445 1999 315-320
13. S.H. Oh T.M. Muzzonigro S.H. Bae et al. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes Laboratory Investigation 84 2004 607-617
14. Y.C. Patel Somatostatin and its receptor family Frontiers in Neuroendocrinology 20 1999 157-198
15. L.N. Moller C.E. Stidsen B. Hartmann J.J. Holst Somatotatin receptors Biochimica et Biophysica Acta 1616 2003 1-84
16. G. Weckbecker I. Lewis R. Albert et al. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects Nature Reviews Drug Discovery 2 2003 999-1017
17. M.Z. Strowski M. Kohler H.Y. Chen et al. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis Molecular Endocrinology 17 2003 93-106
18. M.Z. Strowski R.M. Parmar A.D. Blake J.M. Schaeffer Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice Endocrinology 141 2000 111-117
19. M. Rocheville D.C. Lange U. Kumar et al. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity Science 288 2000 154-157
20. J. Binimelis S.M. Webb J. Mones et al. Circulating immunoreactive somatostatin in gastrointestinal diseases. Decrease after vagotomy and enhancement in active ulcerative colitis, irritable bowel syndrome, and duodenal ulcer Scandinavian Journal of Gastroenterology 22 1987 931-937
21. S.O. Gopel T. Kanno S. Barg P. Rorsman Patch-clamp characterisation of somatostatin-secreting-cells in intact mouse pancreatic islets Journal of Physiology 528 2000 497-507
22. J.R. Grider Neurotransmitters mediating the intestinal peristaltic reflex in the mouse Journal of Pharmacology and Experimental Therapeutics 307 2003 460-467
23. F. Abdu G.A. Hicks G. Hennig et al. Somatostatin sst(2) receptors inhibit peristalsis in the rat and mouse jejunum American Journal of Physiology. Gastrointestinal and Liver Physiology 282 2002 G624-G633
24. F. De Jonge L. Van Nassauw J.G. De Man et al. Effects of Schistosoma mansoni infection on somatostatin and somatostatin receptor 2A expression in mouse ileum Neurogastroenterology and Motility 15 2003 149-159
25. F.C. Brunicardi A. Atiya S. Moldovan et al. Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas Pancreas 27 2003 e84-e89
26. N. Hope G. Butt I. Ross et al. Somatostatin enhances cAMP-dependent short-circuit current in human colon via somatostatin receptor subtype-2 Digestive Diseases and Sciences 46 2001 2499-2503
27. C. Chisholm G.R. Greenberg Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures Amercian Journal of Physiology. Endocrinology and Metabolism 283 2002 E311-E317
28. I.M. Joseph Y. Zavros J.L. Merchant D. Kirschner A model for integrative study of human gastric acid secretion Journal of Applied Physiology 94 2003 1602-1618
29. M. Komasaka S. Horie K. Watanabe T. Murayama Antisecretory effect of somatostatin on gastric acid via inhibition of histamine release in isolated mouse stomach European Journal of Pharmacology 452 2002 235-243
30. E. Ekblad Q. Mei F. Sundler Innervation of the gastric mucosa Microscopy Research Techniques 48 2000 241-257
31. R. Hakanson D. Chen E. Lindstrom et al. Control of secretion from rat stomach ECL cells in situ and in primary culture Scandinavian Journal of Clinical and Laboratory Investigation/Supplement 234 2001 53-60
32. M. Levite Y. Chowers Nerve-driven immunity: Neuropeptides regulate cytokine secretion of T cells and intestinal epithelial cells in a direct, powerful and contextual manner Annals of Oncology 12 supplement 2 2001 S19-S25
33. Y. Chowers L. Cahalon M. Lahav et al. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells Journal of Immunology 165 2000 2955-2961
34. P. Tomassetti M. Migliori S. Lalli et al. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours Annals of Oncology 12 supplement 2 2001 S95-S99
35. R. Brentjens L. Saltz Islet cell tumors of the pancreas: The medical oncologist's perspective Surgical Clinics of North America 81 2001 527-542
36. E. Ballare L. Persani A.G. Lania Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment Journal of Clinical Endocrinology and Metabolism 86 2001 3809-3814
37. J. Torrisani M. Bouisson E. Puente et al. Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism Gastroenterology 120 2001 200-209
38. M.J. Low V. Otero-Corchon A.F. Parlow et al. Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth Journal of Clinical Investigation 107 2001 1571-1580
39. V. Martinez A.P. Curi B. Torkian et al. High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice Gastroenterology 114 1998 1125-1132
40. Y. Zavros S. Rathinavelu J.Y. Kao et al. Treatment of Helicobacter gastritis with IL-4 requires somatostatin Proceedings of the National Academy of Sciences of the USA 100 2003 12944-12949
41. S. Yamamoto H. Kaneko T. Konagaya et al. Interactions among gastric somatostatin, interleukin-8 and mucosal inflammation in Helicobacter pylori-positive peptic ulcer patients Helicobacter 6 2001 136-145
42. T. Hayakawa H. Kaneko T. Konagaya et al. Enhanced somatostatin secretion into the gastric juice with recovery of basal acid output after Helicobacter pylori eradication in gastric ulcers Journal of Gastroenterology and Hepatology 18 2003 505-511
43. I.M. Joseph D. Kirschner A model for the study of Helicobacter pylori interaction with human gastric acid secretion Journal of Theoretical Biology 228 2004 55-80
44. A.S. Milutinovic V. Todorovic T. Milosavljevic et al. Somatostatin and D cells in patients with gastritis in the course of Helicobacter pylori eradication: A six-month, follow-up study European Journal of Gastroenterology and Hepatology 15 2003 755-766
45. R. Lewis et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential Journal of Medicinal Chemistry 46 2003 2334-2344
46. S.P. Rohrer E.T. Birzin R.T. Molsey et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry Science 282 1998 737-740
47. L. Yang S.C. Berk S.P. Rohrer et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2 Proceedings of the National Academy of Sciences of the USA 95 1998 10836-10841
48. C. Nunn P. Schoeffter D. Langenegger D. Hoyer Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806 Naunyn Schmiedebergs Archives of Pharmacology 367 2003 1-9
49. L. Poitout P. Roubert M.O. Contour-Galcera et al. Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity Journal of Medicinal Chemistry 44 2001 2990-3000
50. S.W. Lamberts A.J. van der Lely W.W. de Herder L.J. Hofland Octreotide New England Journal of Medicine 334 1996 246-254
51. M.T. Barakat K. Meeran S.R. Bloom Neuroendocrine tumours Endocrine Related Cancer 11 2004 1-18
52. W.W. de Herder E.P. Krenning C.H. Van Eijck S.W. Lamberts Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas Endocrine Related Cancer 11 2004 19-34
53. S. Faiss U.F. Pape M. Bohmig et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group Journal of Clinical Oncology 21 2003 2689-2696
54. W.W. de Herder S.W. Lamberts Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors Endocrine 20 2003 285-290
55. A. Lavy K. Yasin Octreotide for enterocutaneous fistulas of Crohn's disease Canadian Journal of Gastroenterology 17 2003 555-558
56. K.M. Comar A.J. Sanyal Portal hypertensive bleeding Gastroenterology Clinics of North America 32 2003 1079-1105
57. A.K. Kubba H. Dallal G.H. Haydon et al. The effect of octreotide on gastroduodenal blood flow measured by laser Doppler flowmetry in rabbits and man American Journal of Gastroenterology 94 1999 1077-1082
58. H. Reynaert A. Geerts Pharmacological rationale for the use of somatostatin and analogues in portal hypertension Alimentary Pharmacology and Therapeutics 18 2003 375-386
59. C.C. Sieber C. Beglinger S. Bart et al. Lanreotide effect on splanchnic blood flow in healthy subjects: Effect of the rate of infusion Clinical Pharmacology and Therapeutics 75 2004 70-79
60. M. Saruc M. Can N. Kucukmetin et al. Somatostatin infusion and hemodynamic hanges in patients with non-variceal upper gastrointestinal bleeding: A pilot study Medical Science Monitor 9 2003 PI84-PP87
61. D. Gonzalez B.J. Elizondo S. Haslag et al. Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome Journal of Pediatric Gastroenterology and Nutrition 33 2001 183-188
62. P. Orsi C. Guatti-Zuliani L. Okolicsanyi Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract Digestive and Liver Disorders 33 2001 330-334
63. R.T. Poon C. Yeung C.L. Liu et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: A randomised controlled trial Gut 52 2003 1768-1773
64. D. Arvanitidis G.K. Anagnostopoulos D. Giannopoulos et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial Journal of Gastroenterology and Hepatology 19 2004 278-282
65. R.W. Leong A.K. House G.P. Jeffrey Chylous ascites caused by portal vein thrombosis treated with octreotide Journal of Gastroenterology and Hepatology 18 2003 1211-1213
66. G. Sener K. Paskaloglu C. Kapucu et al. Octreotide ameliorates alendronate-induced gastric injury Peptides 25 2004 115-121
67. K. Vondra M. Voborska M. Kvapil et al. Somatostatin: Beneficial effects on remission in young adult patients with newly diagnosed diabetes mellitus type 1 Physiology Research 53 2004 115-117
68. B.O. Boehm The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes Expert Opinion on Investigational Drugs 12 2003 1501-1509
69. B.O. Boehm R.H. Lustig Use of somatostatin receptor ligands in obesity and diabetic complications Best Practice and Reseach. Clinical Endocrinology and Metabolism 16 2002 493-509
70. R.J. Lieverse J.B. Jansen A.M. Masclee C.B. Lamers Effects of somatostatin on human satiety Neuroendocrinology 61 1995 112-116
71. G. Scalera G. Tarozzi Somatostatin administration modifies food intake, body weight, and gut motility in rat Peptides 19 1998 991-997
72. A.M. Haqq D.D. Stadler R.G. Rosenfeld et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome Journal of Clinical Endocrinology and Metabolism 88 2003 3573-3576
73. M. Shimada Y. Date M.S. Mondal et al. Somatostatin suppresses ghrelin secretion from the rat stomach Biochemical and Biophysical Research Communications 302 2003 520-525
74. H. Norrelund T.K. Hansen H. Orskov et al. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin Clinical Endocrinology (Oxford) 57 2002 539-546
75. C. Scarpignato The place of octreotide in the medical management of the dumping syndrome Digestion 57 supplement 1 1996 114-118
76. F. Gibril R.T. Jensen Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours Digestive and Liver Disorders 36 supplement 1 2004 S106-S120
77. D.J. Kwekkeboom E.P. Krenning Somatostatin receptor imaging Seminars in Nuclear Medicine 32 2002 84-91
78. G.D. Slooter A. Mearadji W.A. Breeman et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours British Journal of Surgery 88 2001 31-40
79. I. Neumann S. Mirzaei R. Birck et al. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis Rheumatology (Oxford) 43 2004 195-201
80. V.A. Dalm P.M. van Hagen E.P. Krenning The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis Quarterly Journal of Nuclear Medicine 47 2003 270-278
81. W. Cholewinski J.R. Kowalczyk B. Stefaniak et al. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue Tc-depreotide European Journal of Nuclear Medicine and Molecular 2004
82. M. Gotthardt L.M. Dirkmorfeld M.U. Wied et al. Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: An analysis in 188 patients Digestion 68 2003 80-85
83. 68Ga] DOTATOC Journal of Nuclear Medicine 42 2001 1053-1056
84. B. Szende G. Keri TT-232: A somatostatin structural derivative as a potent antitumor drug candidate Anticancer Drugs 14 2003 585-588
85. P. Dasgupta Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis Pharmacology and Therapeutics 102 2004 61-85
86. M. Hejna M. Schmidinger M. Raderer The clinical role of somatostatin analogues as antineoplastic agents: Much ado about nothing? Annals of Oncology 13 2002 653-668
87. M. Raderer M.H. Hejna C. Muller et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo International Journal of Oncology 16 2000 1197-1201
88. H. Lahlou N. Saint-Laurent J.P. Esteve et al. sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation Journal of Biological Chemistry 278 2003 39356-39371
89. D.Y. Pan J.G. Qiao J.W. Chen et al. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial Hepatobiliary and Pancreatic Diseases International 2 2003 211-215
90. D.L. Reidy J.D. Schwartz Therapy for unresectable hepatocellular carcinoma: Review of the randomized clHnical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma Anticancer Drugs 15 2004 427-437
91. J.M. Schwartz J.M. Ham Treatment of hepatocellular carcinoma Current Treatment Options in Gastroenterology 6 2003 465-472
92. W.W. de Herder S.W. Lamberts Somatostatin and somatostatin analogues: diagnostic and therapeutic uses Current Opinion in Oncology 14 2002 53-57
93. M. Pawlikowski G. Melen-Mucha Perspectives of new potential therapeutic applications of somatostatin analogs Neuroendocrinology Letters 24 2003 21-27
94. V.J. Lewington Targeted radionuclide therapy for neuroendocrine tumours Endocrine Related Cancer 10 2003 497-501
95. V.J. Lewington S.E. Clarke Isotopic evaluation and therapy in patients with malignant endocrine disease Best Practice and Research. Clinical Endocrinology and Metabolism 15 2001 225-239
96. I. Virgolini K. Britton J. Buscombe et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial Seminars in Nuclear Medicine 32 2002 148-155
97. D. Bushnell T. O'Dorisio Y. Menda et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors Journal of Nuclear Medicine 44 2003 1556-1560
98. S.A. Celinski W.E. Fisher F. Amaya et al. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts Journal of Surgical Research 115 2003 41-47
99. P. Rochaix N. Delesque J.P. Esteve et al. Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer Human Gene Therapy 10 1999 995-1008
100. D.J. Buchsbaum Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs Seminars in Nuclear Medicine 34 2004 32-46